3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Fluorouracil
10
Oxaliplatin
8
Capecitabine
7
Specimen Handling
6
Nivolumab
6
Leucovorin
6
trastuzumab deruxtecan
5
Magnetic Resonance Spectroscopy
5
pembrolizumab
4
fludarabine
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Cisplatin
4
Biopsy
4
aldesleukin
3
Trastuzumab
3
zimberelimab
2
ulixertinib
2
fludarabine phosphate
2
Ramucirumab
2
Irinotecan
2
Folfox protocol
2
zolbetuximab
1
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
toripalimab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.